A5005474369- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- Cancer and Skin Lesions
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Salivary Gland Tumors Diagnosis and Treatment
- Gene expression and cancer classification
- Cancer Cells and Metastasis
- Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- AI in cancer detection
- Sarcoma Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Monoclonal and Polyclonal Antibodies Research
- Global Cancer Incidence and Screening
- Advanced Biosensing Techniques and Applications
- Bioinformatics and Genomic Networks
- Cervical Cancer and HPV Research
- Molecular Biology Techniques and Applications
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Ovarian cancer diagnosis and treatment
- Breast Implant and Reconstruction
- Neuroendocrine Tumor Research Advances
University of Pittsburgh Medical Center
2013-2025
Magee-Womens Research Institute
2016-2025
UPMC Hillman Cancer Center
2009-2025
Cancer Research Center
2012-2025
PreludeDx (United States)
2022-2024
University of Pittsburgh
2014-2023
University of Hawaiʻi at Mānoa
2020-2022
University of Hawaii Cancer Center
2020-2022
Magee-Womens Hospital
2011-2020
Bialystok University of Technology
2018-2019
We have developed an in vitro muscle preparation suitable for metabolic studies with human tissue and investigated the effects of obesity non-insulin-dependent diabetes mellitus (NIDDM) on glucose transport. Transport 3-O-methylglucose 2-deoxyglucose was stimulated approximately twofold by insulin from normal nonobese subjects stimulation occurred physiological range concentrations. In contrast to transport normal, subjects, morbidly obese or without NIDDM, were not responsive insulin....
There are limited data that compare the usefulness of mammaglobin with gross cystic disease fluid protein-15 (GCDFP-15) in identification breast carcinomas. Whole tissue sections 29 carcinomas matched lymph node metastases and 63 on microarray were stained cocktail GCDFP-15 antibodies. In addition, microarrays (US Biomax, Rockville, MD) containing 544 different human tumors also antibody cocktail. Positive staining was seen 67 (55.4%) 121 28 cases (23.1%) GCDFP-15. majority cases, intensity...
Different immunohistochemical sex cord-stromal markers have been previously studied in various types of ovarian tumors; however, the sensitivity for lineage may vary between markers, and some not be as sensitive tumors compared with other this spectrum neoplasms. The goals study were to determine which are most immunohistochemically robust within a given type tumor, establish whether there substantial differences expression these different tumors. Immunohistochemical stains known variable...
Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen receptor (ER)-positive breast cancers. The result reported as recurrence score ranging from 0 to 100, divided into low-risk (<18), intermediate-risk (18-30), and high-risk (≥31) categories. Our pilot study showed that can be predicted by an equation incorporating standard morphoimmunohistologic variables (referred original Magee equation). Using data set of 817 cases, we formulated three...
HER2 (ERBB2) status is an important prognostic and predictive marker in breast carcinoma. In recent years, Genomic Health (GHI), purveyors of the Oncotype DX test, has been separately reporting by reverse transcription polymerase chain reaction (RT-PCR) to oncologists. Because lack independent evaluation, this quality assurance study was undertaken define concordance rate between immunohistochemistry (IHC)/fluorescent situ hybridization (FISH) GHI RT-PCR assay.All patients at three...
Complete pathologic response to neoadjuvant chemotherapy (NACT) is predominantly seen in "ERBB2" and "basal-like" tumors using expression profiling. We hypothesize that a similar could be predicted semiquantitative immunohistochemistry for estrogen receptors (ER), progesterone (PR), human epidermal growth factor receptor 2 (HER2).ER, PR, HER2 were used classify 359 treated with NACT into 6 groups: luminal A (strong ER+, negative), B (weak moderate triple negative (negative ER, HER2), ERBB2...
Invasive lobular carcinoma (ILC) is a histologic subtype of breast cancer that frequently associated with favorable outcomes, as approximately 90% ILC express the estrogen receptor (ER). However, recent retrospective analyses suggest patients receiving adjuvant endocrine therapy may not benefit much invasive ductal carcinoma. On basis these observations, we characterized ER function and response in models. The ER-positive cell lines MDA MB 134VI (MM134) SUM44PE were used to examine...
Breast cancer management depends on biomarkers including estrogen receptor, progesterone and human epidermal growth factor receptor 2 (ER/PR/HER2). Though existing scoring systems are widely used well-validated, they can involve costly preparation variable interpretation. Additionally, discordances between histology expected biomarker findings prompt repeat testing to address biological, interpretative, or technical reasons for unexpected results.We developed three independent deep learning...
Histologic grading of breast cancer involves review and scoring three well-established morphologic features: mitotic count, nuclear pleomorphism, tubule formation. Taken together, these features form the basis Nottingham Grading System which is used to inform characterization prognosis. In this study, we develop deep learning models perform histologic all components using digitized hematoxylin eosin-stained slides containing invasive carcinoma. We first evaluate model performance...
The expression of aromatase by breast cancer cells and the role locally produced estrogen in stimulation tumor growth has been controversial. present study was performed to determine site aromatization human cancers, using both immunocytochemistry situ hybridization. functional significance estrogens on addressed measuring activity a marker proliferation (PCNA score). In addition, histocultures some tumors were carried out investigate whether testosterone could stimulate proliferation. Of 19...
We examined the distribution of high- and low-molecular-weight cytokeratins, vimentin, carcinoembryonic antigen (CEA) in normal endometrial glands endocervical (20 cases each) adenocarcinomas (29 15 respectively). Low- high-molecular-weight cytokeratin staining was present epithelium carcinomas. Coexpression vimentin universally proliferative glands, with marked decrease or absence secretory phase patterns. Vimentin had a perinuclear within cells, contrast to which stained diffusely. found...
The distinction between lobular and ductal lesions of the breast is important in several circumstances. Diagnostic reproducibility versus lesions, based on histology alone, less than optimal. proper atypical hyperplasia, carcinoma situ low-grade critical for patient management. Patients who have a core biopsy invasive often preoperative magnetic resonance imaging to prepare surgeon margin attainment. E-cadherin, negative membrane marker neoplasia, useful but as marker, can be difficult...
Estrogen receptor (ER) status in breast cancer is currently the most important predictive biomarker that determines prognosis after treatment with endocrine therapy. Although immunohistochemistry has been widely viewed as gold standard methodology for ER testing cancer, lack of standardized procedures, and regulatory adherence to guidelines resulted high rates "false-negative" results worldwide. Standardized only possible all aspects testing—preanalytical, analytical, postanalytical, have...